Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Coya Therapeutics, Inc. (NASDAQ: COYA) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, which document its status as a Nasdaq-listed clinical-stage biotechnology company and outline key corporate, financing, and clinical development events. Coya’s common stock, par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol COYA, as noted in multiple Form 8-K filings.
In its recent current reports on Form 8-K, Coya has disclosed material events such as milestone payments received under a Development and License Agreement with Dr. Reddy’s Laboratories Ltd. tied to FDA acceptance of an Investigational New Drug (IND) application for COYA 302 in amyotrophic lateral sclerosis (ALS) and dosing of the first patient in the Phase 2 ALSTARS Trial. Other 8-K filings describe the submission and resubmission of the IND for COYA 302, FDA review timelines, and acceptance of a Clinical Trial Application (CTA) by Health Canada.
Filings also cover capital markets activity, including an Underwriting Agreement for an underwritten public offering of common stock and related details such as the number of shares offered, offering price, estimated gross proceeds, and issuance of warrants to a financial advisor. Additional 8-Ks report quarterly financial results via furnished press releases, as well as outcomes of the company’s annual meeting of stockholders, including director elections and auditor ratification.
On Stock Titan, Coya’s SEC filings are updated as new documents are posted to EDGAR. Users can review 8-Ks related to clinical milestones, financing transactions, and governance matters, alongside other periodic and registration statements, while AI-powered tools help summarize key points and highlight items such as trial progress, milestone payments, and changes affecting COYA shareholders.
Coya Therapeutics, Inc. reported a new equity award to its Chief Executive Officer, Swaminathan Arun. On January 22, 2026, he received a stock option covering 293,983 shares of common stock with an exercise price of $4.73 per share.
These options were granted at a price of $0 for the derivative itself and are held directly. The shares underlying the option vest in monthly installments over 36 months, conditioned on continued service. If there is a change in control of Coya Therapeutics, all unvested shares under this option will vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.
Coya Therapeutics, Inc. filed a current report describing a stockholder letter that updates its financial position and key clinical milestone timing. The company reported an unaudited cash balance of $46.8 million as of December 31, 2025, and stated it has a projected cash runway into the second half of 2027, indicating it currently expects to fund operations for an extended period. Coya also noted that it expects a topline data readout from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027, giving investors a timeframe for when important clinical results may become available.
Coya Therapeutics reported early clinical data from an investigator-initiated, open-label proof-of-concept study using a combination of low-dose IL-2 and CTLA4-Ig in 9 patients with Frontotemporal Dementia over about six months. Patients received subcutaneous CTLA4-Ig plus a 5-day course of low-dose IL-2 every four weeks for a total of 22 weeks of dosing and follow-up.
The treatment was generally well tolerated: the most common side effect was mild injection-site redness in 33.3% of individuals, and no serious adverse events were observed. Measures of regulatory T cell (Treg) activity and markers such as CD25 and FOXP3 showed significant increases as early as two weeks after dosing and remained elevated through week 22.
Cognitive outcomes, measured by Montreal Cognitive Assessment and CDR-FTLD scores, were essentially stable from baseline (MOCA 13.5; CDR-FTLD 4.8) to week 22 (MOCA 14; CDR-FTLD 5.5), suggesting no notable decline in cognitive or functional status over the treatment period in this small group.
Coya Therapeutics director Anabella Villalobos received a grant of stock options covering 10,000 shares of common stock. The options were granted on January 2, 2026 with an exercise price of $5.65 per share and no cost to receive the award. The filing reports that Villalobos now beneficially owns 10,000 derivative securities directly.
According to the vesting terms, 100% of the option will vest on the first anniversary of the grant date, as long as continuous service is maintained. The options are scheduled to expire on January 2, 2036 if not exercised.
Coya Therapeutics, Inc. reported that director Wilbur L. Ross Jr. received a new stock option award. On January 2, 2026, he was granted a stock option to buy 10,000 shares of Coya common stock at an exercise price of $5.65 per share. The option was granted at no cost and is held directly.
Subject to his continuous service, 100% of the option will vest on the first anniversary of the grant date, meaning it becomes fully exercisable after one year. The option is scheduled to expire on January 2, 2036 if not exercised. Following this grant, he beneficially owns 10,000 derivative securities in the form of this option.
Coya Therapeutics, Inc. director Lee Ann reported receiving a stock option grant. On January 2, 2026, she was granted a stock option to buy 10,000 shares of common stock with an exercise price of $5.65 per share.
The option was granted for no cash cost and is held directly. Subject to continuous service, 100% of the option vests on the first anniversary of the grant date. The option becomes exercisable on January 2, 2027 and is scheduled to expire on January 2, 2036. Following this grant, Lee Ann beneficially owns 10,000 derivative securities in the form of this option.
Coya Therapeutics, Inc. received a $4.2 million milestone payment under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories SA.
The payment was triggered when the first patient was dosed in Coya’s ALSTARS clinical trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The first patient dosing in ALSTARS was previously announced on December 9, 2025, marking a key development step for the COYA 302 ALS program.
Coya Therapeutics (COYA) reported Q3 results. Collaboration revenue was $3,564,254, driven by the DRL Development Agreement. Operating expenses were $5,997,151, and the company recorded a net loss of $2,115,831, or $0.13 per share.
Cash and cash equivalents were $28,129,866 as of September 30, 2025. Deferred collaboration revenue totaled $2,007,979. Shares outstanding were 16,742,638 as of quarter end; this is a baseline figure, not the amount being offered.
After quarter end, Coya completed an underwritten public offering of 4,181,818 shares at $5.50 per share for approximately $23.0 million in gross proceeds. Management states that existing cash together with these proceeds is expected to fund operations for at least one year after the statements are issued.
Coya Therapeutics, Inc. filed a current report to note that it issued a press release on November 12, 2025 disclosing information about its results of operations for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 under Item 2.02, and the same information is also referenced under Item 7.01 for Regulation FD disclosure. The company states that this information is being furnished, not filed, so it is not subject to liability under Section 18 of the Exchange Act unless later specifically incorporated by reference into another filing.
Coya Therapeutics (COYA) priced an underwritten public offering. The company agreed to sell 4,181,818 shares of common stock, including 545,454 from the underwriter’s fully exercised option, at $5.50 per share. Gross proceeds are estimated at approximately $23.0 million before fees and expenses, with closing expected on or about October 27, 2025, subject to customary conditions.
The deal was conducted under an effective Form S-3, with Lucid Capital Markets as underwriter. Directors and executive officers entered lock-up agreements restricting sales through January 22, 2026. Allele Capital Partners, via Wilmington Capital Securities, acted as financial advisor; the company will pay $200,000 and issue warrants for 100,000 shares at a $5.50 exercise price under a private placement exemption.